PEARSON, Andrew D J, Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA, Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA a Gilles VASSAL. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer. Oxford: Elsevier Science Inc., 2022, roč. 160, January 2022, s. 112-133. ISSN 0959-8049. Dostupné z: https://dx.doi.org/10.1016/j.ejca.2021.10.016.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Autoři PEARSON, Andrew D J (garant), Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA (203 Česká republika, domácí), Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA a Gilles VASSAL.
Vydání European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 8.400
Kód RIV RIV/00216224:14110/22:00128488
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.ejca.2021.10.016
UT WoS 000792599600009
Klíčová slova anglicky Paediatric oncology; CAR T-cell; Adoptive cellular immunotherapy; Paediatric Strategy Forum; Drug development; Cancer therapeutics
Štítky 14110321, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 1. 2. 2023 14:29.
Anotace
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children.
VytisknoutZobrazeno: 28. 7. 2024 20:31